欧美日本一道本一区二区_亚洲免费影视_91手机在线看片_精品欧美成人高清在线观看_少妇作爱bbbb免费看_51久久夜色精品国产水果派解说

百濟神州 BeiGene  
百濟神州是一家總部設在北京的中國生命科學生物科技公司，致力于探索和開發(fā)對中國和亞太地區(qū)常見癌癥有效的新型抗腫瘤藥物。

我們的研發(fā)策略將包括開發(fā)我們自己在中國實驗室發(fā)現(xiàn)的新藥和從合作伙伴引進的對中國和亞太地區(qū)常見癌癥有潛在療效的新藥。

為完善我們的研發(fā)能力，百濟神州正在中國創(chuàng)造一個從實驗室到臨床試驗的強大整合研發(fā)平臺，用于識別癌癥患者中最有可能受益于相關藥物或治療方法的病人亞群。通過理解對藥物的敏感性和靶標分子之間的關系, 我們將會研發(fā)出更有效和更安全的新藥。

我們正在以下領域建立杰出的團隊：

全新的小分子藥物和生物藥物的研發(fā)
側重于在患者中對生物標志物識別和確認的轉化研究
基于人類腫瘤基因分型和基因表達譜的生物信息學
2個中國臨床試驗項目
以下幾個方面實力的結合帶給我們獨特的優(yōu)勢：

中國和西方的研發(fā)知識和臨床實踐
大制藥公司的嚴謹性和穩(wěn)健性與小生物技術公司的創(chuàng)業(yè)精神
中國和西方的創(chuàng)業(yè)文化
百濟神州總部設立于中國北京。

BeiGene is a Chinese life sciences biotechnology company based in Beijing that is focused on discovering and developing innovative oncology drugs that will address unmet medical needs in cancers that are prevalent in China and the Asia-Pacific region.

Our compound portfolio will encompass novel drugs that evolve out of our discovery laboratories in China that have potential for high impact in the treatment of Chinese and Asian cancers.

To complement our discovery and development capabilities, BeiGene is creating a robust platform in China to enable the identification of specific subsets of patient populations that will identify patients who are most likely to benefit from the use of specific drugs or treatments. Understanding the link between treatment sensitivity and molecular targets will direct us to develop future drug candidates with greater efficacy and safety.

We are building core excellence in:

novel drug discovery in the areas of both small molecules and biologicals
translational research with an emphasis on biomarker identification and validation in patients
bioinformatics based on human tumor genotyping and expression profiling
2 China clinical development
Our unique organization synergistically combines the strengths of:

Chinese and Western scientific knowledge and medical practice
rigor and robustness from large pharma with biotech entrepreneurialism
Chinese and Western start-up culture
BeiGene is headquartered and operates from Beijing, China.